S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Price, News & Analysis

$23.01
+0.02 (+0.09%)
(As of 03/11/2024)
Today's Range
$22.99
$23.02
50-Day Range
$22.31
$23.01
52-Week Range
$3.11
$23.21
Volume
6.62 million shs
Average Volume
1.52 million shs
Market Capitalization
$389.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.25

Harpoon Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
18.4% Upside
$27.25 Price Target
Short Interest
Healthy
4.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
0.00mentions of Harpoon Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$492.14 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($4.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.50 out of 5 stars

Medical Sector

117th out of 939 stocks

Biotechnology Industry

1st out of 13 stocks

HARP stock logo

About Harpoon Therapeutics Stock (NASDAQ:HARP)

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

HARP Stock Price History

HARP Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
HARP Sep 2024 20.000 put
HARP Apr 2024 20.000 put
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
Harpoon Therapeutics just downgraded at Citi, here's why
HARPOON THERAPEUTICS (5HTA.BE)
Harpoon Therapeutics Inc. (5HTA.SG)
Stock (HARP), Short Interest Report
See More Headlines
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2023
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
53
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.25
High Stock Price Target
$40.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-67,730,000.00
Pretax Margin
-81.67%

Debt

Sales & Book Value

Annual Sales
$37.34 million
Book Value
$1.63 per share

Miscellaneous

Free Float
14,054,000
Market Cap
$389.61 million
Optionable
Optionable
Beta
2.11
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Ms. Julie M. Eastland M.B.A. (Age 60)
    President, CEO, Secretary & Director
    Comp: $910.77k
  • Dr. Luke N. Walker M.D. (Age 52)
    Chief Medical Officer
    Comp: $424.43k
  • Mr. Michael Eric Faerm (Age 57)
    Interim Chief Financial Officer
  • Dr. Chatan Charan Ph.D.
    Senior Vice President of Product Development, Technical & Manufacturing Operations
  • Mr. James B. Bucher J.D. (Age 58)
    Chief Legal Officer
  • Ms. Wendy Chang
    Chief People Officer
  • Dr. Banmeet Anand Ph.D.
    Senior Vice President of Translational Medicine
  • Mr. Haibo Wang
    Senior Vice President of Business Development

HARP Stock Analysis - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HARP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HARP, but not buy additional shares or sell existing shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price target for 2024?

6 brokers have issued 12-month price targets for Harpoon Therapeutics' stock. Their HARP share price targets range from $23.00 to $40.00. On average, they expect the company's share price to reach $27.25 in the next year. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How have HARP shares performed in 2024?

Harpoon Therapeutics' stock was trading at $11.37 at the beginning of 2024. Since then, HARP stock has increased by 102.4% and is now trading at $23.01.
View the best growth stocks for 2024 here
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 538,400 shares, a decrease of 53.6% from the February 14th total of 1,160,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 0.5 days. Approximately 4.3% of the company's stock are short sold.
View Harpoon Therapeutics' Short Interest
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.70) by $0.80. The company earned $4.09 million during the quarter, compared to analysts' expectations of $11.06 million. Harpoon Therapeutics had a negative net margin of 81.68% and a negative trailing twelve-month return on equity of 893.55%.

When did Harpoon Therapeutics' stock split?

Shares of Harpoon Therapeutics reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

Harpoon Therapeutics (HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include New Leaf Venture Partners L.L.C. (10.98%), Commodore Capital LP (8.86%), Franklin Resources Inc. (8.81%), Vanguard Group Inc. (5.20%), Vanguard Group Inc. (5.20%) and Blackstone Inc. (4.81%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology, Merck & Co, Inc and Ronald Hunt.
View institutional ownership trends
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HARP) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners